Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stamm

Showing results (121-130 of 155) with videos related to

Pageof 16
Sort By:
Journal of Hepatology|June 11, 2018
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipientsKosh Agarwal, Lluís Castells, Beat Müllhaupt, et al.
Journal of Neurotrauma|September 29, 2015
Cavum Septi Pellucidi in Symptomatic Former Professional Football PlayersInga K Koerte, Jakob Hufschmidt, Marc Muehlmann, et al.
Journal of Neurotrauma|February 21, 2013
Profile of self-reported problems with executive functioning in college and professional football playersDaniel R Seichepine, Julie M Stamm, Daniel H Daneshvar, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal|April 22, 2011
Structure and flow of droplets on solid surfacesP Müller-Buschbaum, D Magerl, R Hengstler, et al.
The New England Journal of Medicine|August 6, 1987
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeksW E Dismukes, G Cloud, H A Gallis, et al.
Nature Microbiology|August 31, 2016
Intermediate filaments enable pathogen docking to trigger type 3 effector translocationBrian C Russo, Luisa M Stamm, Matthijs Raaben, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
Hepatology International|February 22, 2019
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in IndiaAjit Sood, Ajay Duseja, Mayank Kabrawala, et al.
Pageof 16

Showing results (121-130 of 155) with videos related to

Sort By:
Pageof 16
Journal of Hepatology|June 11, 2018
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipientsKosh Agarwal, Lluís Castells, Beat Müllhaupt, et al.
Journal of Neurotrauma|September 29, 2015
Cavum Septi Pellucidi in Symptomatic Former Professional Football PlayersInga K Koerte, Jakob Hufschmidt, Marc Muehlmann, et al.
Journal of Neurotrauma|February 21, 2013
Profile of self-reported problems with executive functioning in college and professional football playersDaniel R Seichepine, Julie M Stamm, Daniel H Daneshvar, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal|April 22, 2011
Structure and flow of droplets on solid surfacesP Müller-Buschbaum, D Magerl, R Hengstler, et al.
The New England Journal of Medicine|August 6, 1987
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeksW E Dismukes, G Cloud, H A Gallis, et al.
Nature Microbiology|August 31, 2016
Intermediate filaments enable pathogen docking to trigger type 3 effector translocationBrian C Russo, Luisa M Stamm, Matthijs Raaben, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
Hepatology International|February 22, 2019
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in IndiaAjit Sood, Ajay Duseja, Mayank Kabrawala, et al.
Pageof 16